Creative Planning Buys 3,458 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Creative Planning raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 8.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,033 shares of the company’s stock after buying an additional 3,458 shares during the period. Creative Planning’s holdings in Denali Therapeutics were worth $999,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after buying an additional 1,847 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after purchasing an additional 807 shares during the last quarter. Fisher Asset Management LLC bought a new position in shares of Denali Therapeutics during the 4th quarter valued at $59,000. Headlands Technologies LLC bought a new position in shares of Denali Therapeutics during the 1st quarter valued at $88,000. Finally, SG Americas Securities LLC bought a new position in shares of Denali Therapeutics during the 1st quarter valued at $147,000. Institutional investors own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In other news, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DNLI shares. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a report on Wednesday, September 4th. Wedbush reduced their target price on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a report on Thursday. Finally, Citigroup increased their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $38.33.

Denali Therapeutics Trading Down 2.9 %

NASDAQ:DNLI opened at $25.74 on Friday. The company has a 50-day moving average price of $26.12 and a 200-day moving average price of $22.24. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $32.13. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -26.81 and a beta of 1.38.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same period in the prior year, the business posted $1.30 earnings per share. The company’s revenue for the quarter was down 99.7% on a year-over-year basis. Equities analysts forecast that Denali Therapeutics Inc. will post -2.54 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.